Drug intelligence / Profile preview

CC-02-2

Development stage: Preclinical
Lead developer: CompleCure
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

**CC-02-2** is a preclinical, HER2-targeted antibody-drug conjugate being developed by CompleCure for HER2-positive unresectable advanced or metastatic breast cancer in patients with a history of chemotherapy. The conjugate is intended to bind human epidermal growth factor receptor 2 on tumor cells and deliver a cytotoxic payload following tumor-cell uptake. Sponsor pipeline notes reportedly describe a doxorubicin and auristatin payload approach, although the precise payload architecture and linker have not been publicly detailed.

Targets

TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CC-02-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC-02-2.

Explore the full profile